Lexicon pens licensing deal with Viatris for sotagliflozin

Texas, USA-based Lexicon Pharmaceuticals (Nasdaq: LXRX) announced that Viatris (Nasdaq: VTRS) has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. Lexicon retains sole commercialization rights for sotagliflozin in all indications in the USA and Europe.

Sotagliflozin was approved by the US Food and Drug Administration under the trade name Inpefa in May 2023 to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

In exchange for the rights, Viatris is paying an upfront payment to Lexicon of $25 million, and has committed to potential contingent regulatory and sales milestone payments and tiered royalties ranging from low-double-digit to upper-teens on annual net sales. Viatris will be responsible for all regulatory and commercialization activities for sotagliflozin in the licensed territories. Lexicon will be responsible for providing clinical and commercial supply of sotagliflozin to Viatris at an agreed upon transfer price.